KR20230142482A - 칼리크레인 관련 펩티다제 2 항원 결합 도메인을 포함하는면역접합체 및 이의 용도 - Google Patents

칼리크레인 관련 펩티다제 2 항원 결합 도메인을 포함하는면역접합체 및 이의 용도 Download PDF

Info

Publication number
KR20230142482A
KR20230142482A KR1020237026179A KR20237026179A KR20230142482A KR 20230142482 A KR20230142482 A KR 20230142482A KR 1020237026179 A KR1020237026179 A KR 1020237026179A KR 20237026179 A KR20237026179 A KR 20237026179A KR 20230142482 A KR20230142482 A KR 20230142482A
Authority
KR
South Korea
Prior art keywords
radioactive metal
binding domain
immunoconjugate
antigen binding
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020237026179A
Other languages
English (en)
Korean (ko)
Inventor
페이 센
테레사 맥데빗
샬롬 골드버그
크리스틴 와일리
라이언 엠. 스미스
사티아데비 벤카타라마니
Original Assignee
얀센 바이오테크 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 바이오테크 인코포레이티드 filed Critical 얀센 바이오테크 인코포레이티드
Publication of KR20230142482A publication Critical patent/KR20230142482A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
KR1020237026179A 2021-01-27 2022-01-26 칼리크레인 관련 펩티다제 2 항원 결합 도메인을 포함하는면역접합체 및 이의 용도 Withdrawn KR20230142482A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163142147P 2021-01-27 2021-01-27
US63/142,147 2021-01-27
US202163144586P 2021-02-02 2021-02-02
US63/144,586 2021-02-02
PCT/IB2022/050673 WO2022162549A2 (en) 2021-01-27 2022-01-26 Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses

Publications (1)

Publication Number Publication Date
KR20230142482A true KR20230142482A (ko) 2023-10-11

Family

ID=80447388

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237026179A Withdrawn KR20230142482A (ko) 2021-01-27 2022-01-26 칼리크레인 관련 펩티다제 2 항원 결합 도메인을 포함하는면역접합체 및 이의 용도

Country Status (9)

Country Link
US (1) US20250325718A1 (enExample)
EP (1) EP4284446A2 (enExample)
JP (1) JP2024503924A (enExample)
KR (1) KR20230142482A (enExample)
AU (1) AU2022213825A1 (enExample)
CA (1) CA3205707A1 (enExample)
IL (1) IL304656A (enExample)
MX (1) MX2023008803A (enExample)
WO (1) WO2022162549A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10806806B2 (en) 2016-06-23 2020-10-20 Cornell University Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies
SG11201811482YA (en) 2016-06-23 2019-01-30 Univ Cornell Double targeted constructs to affect tumor kill
KR102724812B1 (ko) 2017-04-05 2024-11-01 코넬 유니버시티 영상화 및 항종양 치료요법에 유용한 조정 가능한 약동학을 갖는 삼작용성 작제물
KR20210116437A (ko) 2018-11-20 2021-09-27 코넬 유니버시티 방사성핵종의 마크로사이클릭 복합체 및 암의 방사선 요법에서의 이의 용도
ES3075769T3 (en) 2019-05-10 2026-08-07 Janssen Biotech Inc Macrocyclic chelators and methods of use thereof
CR20220025A (es) 2019-07-26 2022-05-04 Janssen Biotech Inc Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y sus usos
WO2023084396A1 (en) * 2021-11-09 2023-05-19 Janssen Biotech, Inc. Macrocyclic compounds and methods of making the same
WO2023144723A1 (en) * 2022-01-26 2023-08-03 Janssen Biotech, Inc. Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
WO2003075855A2 (en) * 2002-03-08 2003-09-18 Protein Design Labs, Inc. Antibodies against cancer antigen tmeff2 and uses thereof
AU2006262231B2 (en) * 2005-06-20 2013-01-24 Psma Development Company, Llc PSMA antibody-drug conjugates
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
PL3248462T3 (pl) 2010-03-31 2024-07-08 Ablexis, Llc Modyfikacja myszy metodami inżynierii genetycznej w celu wytworzenia przeciwciał chimerycznych
WO2014093908A2 (en) 2012-12-14 2014-06-19 Omt, Inc. Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
WO2015075445A1 (en) * 2013-11-19 2015-05-28 Fredax Ab Humanised anti kallikrein-2 antibody
US20180326102A1 (en) 2015-11-18 2018-11-15 Memorial Sloan Kettering Cancer Center Systems, methods, and compositions for imaging androgen receptor axis activity in carcinoma, and related therapeutic compositions and methods
ES2992988T3 (en) 2017-03-30 2024-12-20 Univ Cornell Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer
KR20210116437A (ko) 2018-11-20 2021-09-27 코넬 유니버시티 방사성핵종의 마크로사이클릭 복합체 및 암의 방사선 요법에서의 이의 용도
ES3075769T3 (en) 2019-05-10 2026-08-07 Janssen Biotech Inc Macrocyclic chelators and methods of use thereof
CR20220025A (es) * 2019-07-26 2022-05-04 Janssen Biotech Inc Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y sus usos
CN114727632A (zh) 2019-09-27 2022-07-08 J-制油株式会社 加工肉制品的制造方法

Also Published As

Publication number Publication date
JP2024503924A (ja) 2024-01-29
EP4284446A2 (en) 2023-12-06
AU2022213825A1 (en) 2023-09-14
WO2022162549A2 (en) 2022-08-04
WO2022162549A3 (en) 2022-09-29
MX2023008803A (es) 2023-08-04
CA3205707A1 (en) 2022-08-04
US20250325718A1 (en) 2025-10-23
IL304656A (en) 2023-09-01

Similar Documents

Publication Publication Date Title
KR102831970B1 (ko) 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
KR102890653B1 (ko) 항-cd33 항체, 항-cd33/항-cd3 이중특이성 항체, 및 이의 용도
CN110869389B (zh) 抗ror1抗体及其制备和使用方法
KR102361237B1 (ko) 코일드 코일 면역글로불린 융합 단백질 및 이것의 조성물
TWI825834B (zh) 基於艾日布林之抗體-藥物結合物及使用方法
KR20220040483A (ko) 칼리크레인 관련 펩티다제 2 항원 결합 도메인을 포함하는 단백질 및 이의 용도
CN111954680B (zh) IL2Rβ/共同γ链抗体
AU2015292406B2 (en) Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same
KR102096224B1 (ko) 폴리펩티드 구축물 및 이의 용도
KR20230017841A (ko) Cd3 항원 결합 도메인을 포함하는 단백질 및 이의 용도
KR20230041819A (ko) Hla-g 항원-결합 도메인을 포함하는 단백질 및 이의 용도
KR102718129B1 (ko) cys80 접합된 면역글로불린
DK2109622T3 (en) High affinity antibodies neutralizing staphylococcus enterotoxin B
CN112210000A (zh) 突变体白介素-2多肽
KR20220040474A (ko) 항-hK2 키메라 항원 수용체(CAR)
TW202216743A (zh) Ｉｌ－１０突變蛋白及其融合蛋白
CN114007645A (zh) 修饰的抗pd-l1抗体及用于治疗神经退行性疾病的方法和用途
CN114502151B (zh) 抗cd19抗体及其使用和制备方法
RU2834996C1 (ru) Антитела против cd19 и способы их применения и получения
RU2844753C2 (ru) Конъюгаты антитело-лекарственное средство на основе эрибулина и способы применения
HK40044689A (en) Mutant interleukin-2 polypeptides
HK40065811B (en) Anti-cd19 antibodies and methods of using and making thereof
HK40065811A (en) Anti-cd19 antibodies and methods of using and making thereof
EA044746B1 (ru) АНТИТЕЛА И АНТИГЕНСВЯЗЫВАЮЩИЕ ФРАГМЕНТЫ ПРОТИВ ГЛИКОПРОТЕИНА ШИПОВ SARS-CoV-2

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202